Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Biosimilar Labeling: Should FDA Just Throw Up Its Hands And Finalize Guidance?

Executive Summary

Brand and generic industries are on opposite sides of spectrum on most issues; there is mutual opposition, however, to the use of a meaningless four-letter suffix in the proper name of a product.


Related Content

Biosimilar User Fee Agreement Puts FDA On Hook For Delayed Guidances
FDA Biosimilar Policy Continues To Evolve With Approval Of Sandoz Erelzi
FDA To Update Quality Metrics Guidance
Lobbying FDA: AbbVie Questions Humira Biosimilars In Private Meeting
Lobbying FDA: AbbVie Questions Humira Biosimilars In Private Meeting
Biosimilar Labeling Variation From Reference Product OK, FDA Says
Biosimilar Labeling: FDA Says Leave Comparability Data Out
Biosimilar Labeling In US Needs Greater Transparency, BIO And PhRMA Say
AbbVie Seeks Strict Interchangeability Standards For Biosimilars


Related Companies